Insider Transactions in Q1 2024 at Amylyx Pharmaceuticals, Inc. (AMLX)
Insider Transaction List (Q1 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 05
2024
|
Gina Mazzariello Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
1,540
-1.86%
|
$27,720
$18.73 P/Share
|
|
Mar 05
2024
|
James M Frates Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,792
-1.31%
|
$32,256
$18.73 P/Share
|
|
Mar 05
2024
|
Justin B. Klee Co-Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
4,135
-0.14%
|
$74,430
$18.73 P/Share
|
|
Mar 05
2024
|
Joshua B Cohen Co-Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
4,135
-0.14%
|
$74,430
$18.73 P/Share
|
|
Feb 26
2024
|
James M Frates Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+20.83%
|
-
|
|
Feb 26
2024
|
Justin B. Klee Co-Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
126,667
+4.1%
|
-
|
|
Feb 26
2024
|
Joshua B Cohen Co-Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
126,667
+4.02%
|
-
|
|
Feb 26
2024
|
Gina Mazzariello Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
36,667
+30.66%
|
-
|
|
Feb 23
2024
|
Gina Mazzariello Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
2,838
-5.78%
|
$51,084
$18.76 P/Share
|
|
Jan 25
2024
|
George M Milne Jr |
SELL
Bona fide gift
|
Direct |
9,100
-1.19%
|
-
|
|
Jan 16
2024
|
George M Milne Jr |
SELL
Bona fide gift
|
Direct |
94,350
-10.95%
|
-
|
|
Jan 09
2024
|
Joshua B Cohen Co-Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
5,841
-0.2%
|
$93,456
$16.33 P/Share
|
|
Jan 09
2024
|
James M Frates Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,716
-2.37%
|
$43,456
$16.33 P/Share
|
|
Jan 09
2024
|
Justin B. Klee Co-Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
5,841
-0.21%
|
$93,456
$16.33 P/Share
|
|
Jan 09
2024
|
Patrick D Yeramian Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,812
-1.35%
|
$44,992
$16.33 P/Share
|